The global market for urine tumor DNA testing is poised for significant growth, driven by the rising prevalence of urological cancers and an increasing demand for non-invasive cancer diagnostics. According to a recent report added to ResearchAndMarkets.com’s offerings, the market is expected to grow from $1.18 billion in 2025 to $1.36 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%.
Urine tumor DNA testing has gained traction due to advancements in polymerase chain reaction (PCR) technologies and sequencing methods, which have enhanced early cancer detection capabilities. The expansion of diagnostic services in hospitals and laboratories has further solidified the role of these tests in oncology diagnostics, disease monitoring, and treatment planning.
Projections indicate that the market will reach $2.36 billion by 2030, growing at a CAGR of 14.9%. Key factors contributing to this growth include the integration of artificial intelligence in DNA analysis, the development of multiplex assays, and the expansion of personalized medicine. Additionally, the integration with electronic health records and clinical decision support systems is expected to drive demand for high-sensitivity testing, which can facilitate early detection, monitor disease progression, and assess treatment responses.
The increasing incidence of urological cancers is a major driver for the market. As populations age, cancer rates are rising, creating a need for accessible diagnostic and monitoring tools. Urine tumor DNA testing offers a non-invasive method to identify cancer-associated genetic mutations, aiding clinical decision-making without the need for more invasive procedures.
In December 2025, Cancer Australia reported 28,868 new prostate cancer cases, representing about 30% of all new cancer diagnoses among men in the country. This highlights the necessity for innovative molecular diagnostics to enhance early detection and ongoing cancer management.
Technological advancements are transforming the urine tumor DNA testing landscape. Companies are investing in liquid biopsy platforms that improve sample stabilization, DNA preservation, and compatibility with next-generation sequencing workflows. These innovations aim to enhance diagnostic accuracy and standardize sample handling, broadening the application of urine-based testing in both clinical and research settings.
In September 2024, PreAnalytiX, a collaboration between QIAGEN and Becton, Dickinson and Company, introduced a urine-based liquid biopsy solution. This product offers standardized urine collection and efficient DNA preservation, supporting next-generation sequencing applications. It is designed to facilitate earlier cancer detection and more precise biomarker analysis, potentially improving patient management.
Strategic partnerships are also expanding access to urine tumor DNA testing. For instance, in October 2024, Pangea Laboratory partnered with Unilabs to offer the Bladder CARE Assay in Switzerland and other European markets. This collaboration aims to increase the availability of urine-based bladder cancer detection and promote the adoption of advanced molecular oncology diagnostics across Europe.
Key market trends include AI-powered genetic analysis, high-sensitivity DNA detection, liquid biopsy innovations, and non-invasive cancer monitoring. The integration of these technologies with clinical decision support platforms is expected to enhance testing performance and support personalized approaches to urological cancer care.
Regionally, North America was the largest market for urine tumor DNA testing in 2025, benefiting from its advanced healthcare infrastructure and molecular diagnostic capabilities. The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by increasing healthcare investments and technological adoption.
The report covers various market segments, including:
- Technology: PCR-based, next-generation sequencing, and other technologies.
- Product Type: Assay kits, instruments, services.
- Cancer Type: Bladder, prostate, kidney, and other cancers.
- Sample Type: First-morning urine, random urine samples, catheterized urine samples.
- End-User: Hospitals, diagnostic laboratories, research institutes, and others.
Prominent companies in the market include Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Illumina Inc., and QIAGEN N.V., among others. These companies are pivotal in driving innovation and market expansion.
Footnotes:
- The global urine tumor DNA testing market is projected to grow from $1.18 billion in 2025 to $1.36 billion in 2026. Source.
- The market is forecast to reach $2.36 billion by 2030, with a CAGR of 14.9%. Source.
- In December 2025, Cancer Australia estimated 28,868 new prostate cancer cases. Source.
- PreAnalytiX launched a urine-based liquid biopsy solution in September 2024. Source.
Featured Image: Megapixl @ Ipopba